‘Poor Quality’ Submission: CellTrans’ Lantidra BLA Marked By Missing And Incongruent Data

 
• By Sue Sutter
Drug Review Profile: Lantidra
The FDA had to look beyond the missing and inconsistent data in the Lantidra BLA. • Source: Pink Sheet/Shutterstock

More from Drug Review Profiles

More from Product Reviews